In addition, we found that CD276 was highly expressed in the high-risk group, upregulated in HNSCC and helped tumor cells evade immune surveillance (Li et al., 2022), consistent with our predicted results. This evidence concerns the gene CD276 and head and neck squamous cell carcinoma.